Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Assets Average (2011 - 2026)

Lite Strategy (LITS) posted Assets Average of $70.4 million for Q1 2026, down 28.3% on a QoQ basis from $98.1 million in Q4 2025, and up 211.59% year-over-year from $22.6 million in Q1 2025.

Analysis

Lite Strategy (LITS) Assets Average (2011 - 2026) Analysis & Trends

Lite Strategy has reported Assets Average for 16 years, with the latest figure at $70.4 million in Q1 2026.

  • On a quarterly basis, Assets Average rose 211.59% year-over-year to $70.4 million in Q1 2026; TTM through Mar 2026 was $70.4 million, a 211.59% increase from a year earlier, with the FY2025 full-year figure at $29.8 million, down 63.21% from the prior year.
  • Assets Average was $70.4 million for Q1 2026 at Lite Strategy, down from $98.1 million in the prior quarter.
  • The five-year high for Assets Average was $201.9 million in Q1 2022, with the low at $19.5 million in Q2 2025.
  • Average Assets Average over 5 years is $97.2 million, with a median of $89.9 million recorded in 2023.
  • The sharpest annual moves came in 2024 and 2025: Assets Average plunged 71.0% in 2024, then soared 276.47% in 2025.
  • Over 5 years, Assets Average stood at $155.6 million in 2022, then plunged by 42.22% to $89.9 million in 2023, then slumped by 71.0% to $26.1 million in 2024, then jumped by 276.47% to $98.1 million in 2025, then declined by 28.3% to $70.4 million in 2026.
  • The last three Assets Average figures came in at $70.4 million (Q1 2026), $98.1 million (Q4 2025), and $65.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets Avg. (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 94.07 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 52.82 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 26.95 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 41.30 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 11.22 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 5.34 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 30.78 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 5.51 Bn
10 Lite Strategy 38.03 Mn 30.49 Mn - 70.36 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 70.36 Mn
Dec 31, 2025 98.14 Mn
Sep 30, 2025 65.81 Mn
Jun 30, 2025 19.53 Mn
Mar 31, 2025 22.58 Mn
Dec 31, 2024 26.07 Mn
Sep 30, 2024 34.56 Mn
Jun 30, 2024 56.32 Mn
Mar 31, 2024 74.90 Mn
Dec 31, 2023 89.89 Mn
Sep 30, 2023 111.03 Mn
Jun 30, 2023 127.50 Mn
Mar 31, 2023 140.89 Mn
Dec 31, 2022 155.59 Mn
Sep 30, 2022 170.71 Mn
Jun 30, 2022 186.13 Mn
Mar 31, 2022 201.95 Mn
Dec 31, 2021 192.91 Mn
Sep 30, 2021 175.22 Mn
Jun 30, 2021 180.11 Mn